Tag Archives: PerkinElmer

  • PerkinElmer Agrees to Acquire SIRION Biotech

    PerkinElmer Inc. has announced it has entered into an agreement to acquire SIRION Biotech GmbH, a leading, global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021. Headquartered in Munich, Germany, privately held SIRION has approximately 50 employees based […]

  • PerkinElmer Completes Acquisition of Oxford Immunotec

    PerkinElmer, Inc. today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC. PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021. Prahlad Singh, President and CEO at PerkinElmer said, “Oxford Immunotec’s global role in fighting tuberculosis, particularly its trademark product, the T-SPOT®.TB test, and the operations it […]

  • Perkin Elmer Updates Q2 Outlook

    Perkin Elmer Updates Q2 Outlook Perkin Elmer has today revised their outlook for Q2, announcing that they expect growth of approximately 12% for the second quarter ended July 5, 2020. The strong revenue growth was driven by better-than-expected demand for solutions aimed at COVID-19 testing needs across the globe. Demand for the Company’s RT-PCR and […]

  • PerkinElmer Announces Results for Q4 2013

      PerkinElmer announces results for Q4 and full year 2013. Revenues for the full year rose only 2.4% to $2.166 billion but net income rose 135% to $164.8 million from the previous year’s $69.9 million. “We are pleased with our strong finish to the year as we delivered solid performances in adjusted earnings per share growth, […]

  • PerkinElmer Announces Financial Results for Q4 2012

    PerkinElmer Announces Financial Results for the Fourth Quarter of 2012 Revenue growth of 6%; Organic revenue growth of 3% GAAP loss per share from continuing operations of $0.14; Adjusted earnings per share of $0.65 Full year revenue growth of 10%; Organic revenue growth of 5%; Adjusted operating profit margin increase of 100 basis points driving adjusted earnings […]